1
ECHELON STROKE MANAGEMENT EXAM FULL PACKAGE
QUESTIONS ANSWERS AND RATIONALES 2026-27 LATEST UPDATED
VERSION INSTANT DOWNLOAD PDF..!!
The Echelon Stroke Management Certification Exam is a highly specialized, advanced clinical
assessment designed for acute care nurses, stroke coordinators, emergency medicine personnel, and
mid-level clinicians operating within certified stroke centers. This examination evaluates a
candidate's clinical competency in rapid neuroassessment, interpretation of acute neuroimaging,
calculation of exact thrombolytic dosages, and management of systemic post-reperfusion variables.
In acute stroke neurology, clinical decisions are bound by a rigid temporal window where "time is
brain." Milligram calculation errors or mismanaged blood pressure levels can result in catastrophic
hemorrhagic transformations or irreversible ischemic propagation. The exam combines complex,
multi-stage clinical scenarios with technical physiologic metrics. Navigating this evaluation requires
deep analytical synthesis of the National Institutes of Health Stroke Scale (NIHSS), the modified
Rankin Scale (mRS), current American Heart Association/American Stroke Association (AHA/ASA)
guidelines, and standard safety practices. This comprehensive question bank is engineered to
simulate high-stakes evaluation environments, targeting safety-critical protocols. By mastering these
scenario-based inquiries and studying the detailed rationales, candidates will develop the expert
technical intuition required to pass their Echelon stroke certification on the very first attempt.
CORE DOMAINS TESTED
1. Hyperacute Assessment & Stroke Mimics: Recognizing early signs of focal neurological
deficits, calculating the NIHSS under time constraints, and differentiating acute ischemic
stroke from stroke mimics (e.g., hypoglycemia, hemiplegic migraine, conversion disorders).
2. Neuroimaging & Diagnostics: Evaluating non-contrast computed tomography (NCCT) for
early signs of ischemia, calculating the Alberta Stroke Program Early CT Score (ASPECTS), and
identifying large vessel occlusions (LVO) via CT angiography (CTA).
3. Reperfusion Therapeutics & Pharmacology: Managing intravenous thrombolysis (Alteplase
and Tenecteplase) criteria, absolute and relative contraindications, exact multi-step dose
calculations, and mechanical thrombectomy triage protocols.
4. Blood Pressure & Hemodynamic Regulation: Implementing specific blood pressure
parameters prior to, during, and after reperfusion therapies using continuous intravenous
titrations.
5. Post-Stroke Complications & Critical Care: Detecting acute hemorrhagic transformation,
managing elevated intracranial pressure (ICP), managing cerebral edema, treating
hemicraniectomy candidates, and monitoring for dysphagia.
6. Secondary Prevention & Quality Metrics: Formulating discharge strategies based on stroke
etiology (cardioembolic vs. large artery atherosclerosis) and maintaining certified stroke
center core performance metrics.
,2
QUESTIONS 1-200
Q1: A 68-year-old female is brought to the emergency department by
emergency medical services 75 minutes after the sudden onset of
left-sided hemiplegia and sensory loss. Her initial non-contrast head
CT shows no acute intracranial hemorrhage or early ischemic
changes, and her fingerstick glucose is 112 mg/dL. Her blood
pressure is currently 192/114 mmHg. Which of the following is the
most appropriate next step in her pharmacological management
regarding reperfusion therapy?
A) Immediately initiate an intravenous infusion of Tenecteplase at
0.25 mg/kg
B) Administer a 10 mg intravenous bolus of Labetalol over 1 to 2
minutes to lower blood pressure below 185/110 mmHg
C) Begin a continuous Nicardipine infusion at 5 mg/h and titrate up
until the diastolic pressure falls below 90 mmHg
D) Administer Labetalol 10–20 mg intravenously over 1–2 minutes,
monitor blood pressure, and re-evaluate for thrombolysis once BP
is <185/110 mmHg
Rationale: The correct answer is D. To safely administer intravenous
thrombolysis (Alteplase or Tenecteplase), the patient's blood pressure
must be lowered below 185/110 mmHg and maintained below
180/105 mmHg for at least 24 hours post-infusion to minimize the
risk of intracranial hemorrhage. According to AHA/ASA guidelines,
initial safe choices include intravenous boluses of Labetalol (10–20
mg) or Nicardipine infusion. Option B is partially correct but lacks the
complete clinical framework of re-evaluation. Option A is incorrect
because administering thrombolytics while the blood pressure is
≥185/110 mmHg is an absolute contraindication. Option C is incorrect
because dropping the diastolic pressure too low (<90 mmHg) too
,3
rapidly can severely compromise the collateral perfusion within the
ischemic penumbra.
Q2: A 54-year-old male with an acute ischemic stroke is determined
to be an ideal candidate for intravenous Alteplase. The patient
weighs exactly 84 kg. The clinician prepares the medication vial.
What is the correct total dose, the exact bolus amount, and the
duration over which the remaining maintenance infusion must be
delivered?
A) Total dose: 75.6 mg; Bolus: 7.56 mg over 1 minute; Infusion:
68.04 mg over 60 minutes
B) Total dose: 84.0 mg; Bolus: 8.40 mg over 1 minute; Infusion: 75.60
mg over 60 minutes
C) Total dose: 90.0 mg; Bolus: 9.00 mg over 2 minutes; Infusion:
81.00 mg over 30 minutes
D) Total dose: 75.6 mg; Bolus: 15.12 mg over 1 minute; Infusion:
60.48 mg over 90 minutes
Rationale: The correct answer is A. The standard dosing protocol for
intravenous Alteplase (tPA) in acute ischemic stroke is 0.9 mg/kg, up
to a maximum total dose of 90 mg. For a patient weighing 84 kg, the
calculation is 84 kg × 0.9 mg/kg = 75.6 mg. Ten percent of this total
calculated dose must be administered as an initial intravenous bolus
over 1 minute (75.6 mg × 0.10 = 7.56 mg). The remaining 90% of the
dose (68.04 mg) must be infused continuously over exactly 60
minutes. Option B uses an incorrect calculation multiplier of 1.0
mg/kg. Option C represents the maximum absolute cap parameters
incorrectly applied to this weight. Option D utilizes an incorrect bolus
percentage and an elongated infusion time.
Q3: During the continuous intravenous infusion of Tenecteplase for a
patient with an acute right middle cerebral artery occlusion, the
nurse notes sudden neurological deterioration. The patient's NIHSS
, 4
score increases from an 11 to a 22, pupils become sluggish and
unequal, and the patient begins vomiting. What is the absolute
priority sequential action?
A) Increase the rate of the maintenance intravenous fluid to flush the
remaining thrombolytic through the line
B) Discontinue the thrombolytic infusion immediately, obtain
emergency type and crossmatch, and order an emergent non-
contrast head CT
C) Administer a rapid bolus of intravenous Protamine Sulfate to
reverse the Tenecteplase activity
D) Draw an immediate arterial blood gas and prepare the patient for
emergent endotracheal intubation
Rationale: The correct answer is B. Sudden neurological deterioration,
signs of increased intracranial pressure (pupillary asymmetry,
vomiting), and an abrupt spike in the NIHSS score during or shortly
after thrombolytic administration are indicative of symptomatic
intracranial hemorrhage (sICH). The absolute priority is to stop the
thrombolytic infusion immediately to prevent further bleeding, order
an emergent non-contrast head CT to confirm the hemorrhage, and
crossmatch blood products for reversal (cryoprecipitate or
antifibrinolytics). Option A is dangerous and will exacerbate the
bleeding. Option C is incorrect because Protamine Sulfate reverses
Heparin, not fibrin-specific thrombolytics like Tenecteplase. Option D
may eventually be necessary for airway protection but does not
address the immediate localized etiology.
Q4: A 72-year-old male with a history of permanent atrial fibrillation
presents to the stroke center 2 hours after acute onset of aphasia
and right-sided neglect. His daughter states he is compliant with his
home medication, Dabigatran (Pradaxa). His coagulation panel shows
an elevated activated partial thromboplastin time (aPTT) and an
ECHELON STROKE MANAGEMENT EXAM FULL PACKAGE
QUESTIONS ANSWERS AND RATIONALES 2026-27 LATEST UPDATED
VERSION INSTANT DOWNLOAD PDF..!!
The Echelon Stroke Management Certification Exam is a highly specialized, advanced clinical
assessment designed for acute care nurses, stroke coordinators, emergency medicine personnel, and
mid-level clinicians operating within certified stroke centers. This examination evaluates a
candidate's clinical competency in rapid neuroassessment, interpretation of acute neuroimaging,
calculation of exact thrombolytic dosages, and management of systemic post-reperfusion variables.
In acute stroke neurology, clinical decisions are bound by a rigid temporal window where "time is
brain." Milligram calculation errors or mismanaged blood pressure levels can result in catastrophic
hemorrhagic transformations or irreversible ischemic propagation. The exam combines complex,
multi-stage clinical scenarios with technical physiologic metrics. Navigating this evaluation requires
deep analytical synthesis of the National Institutes of Health Stroke Scale (NIHSS), the modified
Rankin Scale (mRS), current American Heart Association/American Stroke Association (AHA/ASA)
guidelines, and standard safety practices. This comprehensive question bank is engineered to
simulate high-stakes evaluation environments, targeting safety-critical protocols. By mastering these
scenario-based inquiries and studying the detailed rationales, candidates will develop the expert
technical intuition required to pass their Echelon stroke certification on the very first attempt.
CORE DOMAINS TESTED
1. Hyperacute Assessment & Stroke Mimics: Recognizing early signs of focal neurological
deficits, calculating the NIHSS under time constraints, and differentiating acute ischemic
stroke from stroke mimics (e.g., hypoglycemia, hemiplegic migraine, conversion disorders).
2. Neuroimaging & Diagnostics: Evaluating non-contrast computed tomography (NCCT) for
early signs of ischemia, calculating the Alberta Stroke Program Early CT Score (ASPECTS), and
identifying large vessel occlusions (LVO) via CT angiography (CTA).
3. Reperfusion Therapeutics & Pharmacology: Managing intravenous thrombolysis (Alteplase
and Tenecteplase) criteria, absolute and relative contraindications, exact multi-step dose
calculations, and mechanical thrombectomy triage protocols.
4. Blood Pressure & Hemodynamic Regulation: Implementing specific blood pressure
parameters prior to, during, and after reperfusion therapies using continuous intravenous
titrations.
5. Post-Stroke Complications & Critical Care: Detecting acute hemorrhagic transformation,
managing elevated intracranial pressure (ICP), managing cerebral edema, treating
hemicraniectomy candidates, and monitoring for dysphagia.
6. Secondary Prevention & Quality Metrics: Formulating discharge strategies based on stroke
etiology (cardioembolic vs. large artery atherosclerosis) and maintaining certified stroke
center core performance metrics.
,2
QUESTIONS 1-200
Q1: A 68-year-old female is brought to the emergency department by
emergency medical services 75 minutes after the sudden onset of
left-sided hemiplegia and sensory loss. Her initial non-contrast head
CT shows no acute intracranial hemorrhage or early ischemic
changes, and her fingerstick glucose is 112 mg/dL. Her blood
pressure is currently 192/114 mmHg. Which of the following is the
most appropriate next step in her pharmacological management
regarding reperfusion therapy?
A) Immediately initiate an intravenous infusion of Tenecteplase at
0.25 mg/kg
B) Administer a 10 mg intravenous bolus of Labetalol over 1 to 2
minutes to lower blood pressure below 185/110 mmHg
C) Begin a continuous Nicardipine infusion at 5 mg/h and titrate up
until the diastolic pressure falls below 90 mmHg
D) Administer Labetalol 10–20 mg intravenously over 1–2 minutes,
monitor blood pressure, and re-evaluate for thrombolysis once BP
is <185/110 mmHg
Rationale: The correct answer is D. To safely administer intravenous
thrombolysis (Alteplase or Tenecteplase), the patient's blood pressure
must be lowered below 185/110 mmHg and maintained below
180/105 mmHg for at least 24 hours post-infusion to minimize the
risk of intracranial hemorrhage. According to AHA/ASA guidelines,
initial safe choices include intravenous boluses of Labetalol (10–20
mg) or Nicardipine infusion. Option B is partially correct but lacks the
complete clinical framework of re-evaluation. Option A is incorrect
because administering thrombolytics while the blood pressure is
≥185/110 mmHg is an absolute contraindication. Option C is incorrect
because dropping the diastolic pressure too low (<90 mmHg) too
,3
rapidly can severely compromise the collateral perfusion within the
ischemic penumbra.
Q2: A 54-year-old male with an acute ischemic stroke is determined
to be an ideal candidate for intravenous Alteplase. The patient
weighs exactly 84 kg. The clinician prepares the medication vial.
What is the correct total dose, the exact bolus amount, and the
duration over which the remaining maintenance infusion must be
delivered?
A) Total dose: 75.6 mg; Bolus: 7.56 mg over 1 minute; Infusion:
68.04 mg over 60 minutes
B) Total dose: 84.0 mg; Bolus: 8.40 mg over 1 minute; Infusion: 75.60
mg over 60 minutes
C) Total dose: 90.0 mg; Bolus: 9.00 mg over 2 minutes; Infusion:
81.00 mg over 30 minutes
D) Total dose: 75.6 mg; Bolus: 15.12 mg over 1 minute; Infusion:
60.48 mg over 90 minutes
Rationale: The correct answer is A. The standard dosing protocol for
intravenous Alteplase (tPA) in acute ischemic stroke is 0.9 mg/kg, up
to a maximum total dose of 90 mg. For a patient weighing 84 kg, the
calculation is 84 kg × 0.9 mg/kg = 75.6 mg. Ten percent of this total
calculated dose must be administered as an initial intravenous bolus
over 1 minute (75.6 mg × 0.10 = 7.56 mg). The remaining 90% of the
dose (68.04 mg) must be infused continuously over exactly 60
minutes. Option B uses an incorrect calculation multiplier of 1.0
mg/kg. Option C represents the maximum absolute cap parameters
incorrectly applied to this weight. Option D utilizes an incorrect bolus
percentage and an elongated infusion time.
Q3: During the continuous intravenous infusion of Tenecteplase for a
patient with an acute right middle cerebral artery occlusion, the
nurse notes sudden neurological deterioration. The patient's NIHSS
, 4
score increases from an 11 to a 22, pupils become sluggish and
unequal, and the patient begins vomiting. What is the absolute
priority sequential action?
A) Increase the rate of the maintenance intravenous fluid to flush the
remaining thrombolytic through the line
B) Discontinue the thrombolytic infusion immediately, obtain
emergency type and crossmatch, and order an emergent non-
contrast head CT
C) Administer a rapid bolus of intravenous Protamine Sulfate to
reverse the Tenecteplase activity
D) Draw an immediate arterial blood gas and prepare the patient for
emergent endotracheal intubation
Rationale: The correct answer is B. Sudden neurological deterioration,
signs of increased intracranial pressure (pupillary asymmetry,
vomiting), and an abrupt spike in the NIHSS score during or shortly
after thrombolytic administration are indicative of symptomatic
intracranial hemorrhage (sICH). The absolute priority is to stop the
thrombolytic infusion immediately to prevent further bleeding, order
an emergent non-contrast head CT to confirm the hemorrhage, and
crossmatch blood products for reversal (cryoprecipitate or
antifibrinolytics). Option A is dangerous and will exacerbate the
bleeding. Option C is incorrect because Protamine Sulfate reverses
Heparin, not fibrin-specific thrombolytics like Tenecteplase. Option D
may eventually be necessary for airway protection but does not
address the immediate localized etiology.
Q4: A 72-year-old male with a history of permanent atrial fibrillation
presents to the stroke center 2 hours after acute onset of aphasia
and right-sided neglect. His daughter states he is compliant with his
home medication, Dabigatran (Pradaxa). His coagulation panel shows
an elevated activated partial thromboplastin time (aPTT) and an
